Creating new treatments for advanced prostate cancer
Development of Novel Targeted Therapeutic Agents for Castration Resistant Prostate Cancer
This study is looking for new ways to help men with castration-resistant prostate cancer by creating small molecules that can better target the cancer's growth and changes in the cells, aiming to improve treatment options when current therapies aren't working.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11098615 on NIH RePORTER |
What this research studies
This research focuses on developing new small molecules that can effectively target both the androgen receptor and epigenetic changes in cells for treating castration-resistant prostate cancer (CRPC). The approach involves inhibiting specific enzymes that modify histones, which play a crucial role in regulating androgen receptor signaling. By addressing the limitations of current treatments, this research aims to create more effective therapies that can prevent cancer progression even when traditional treatments fail.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have not responded adequately to existing therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet developed resistance to current treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced prostate cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While there have been promising preclinical studies on similar approaches, the effectiveness of these new strategies in clinical settings remains to be fully established.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Oyelere, Adegboyega — Georgia Institute of Technology
- Study coordinator: Oyelere, Adegboyega
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.